NDRG2 and cancer: Regarding clinical stage subgroup analysis, a significant relationship was found between NDRG2 expression and prognosis in patients with cancer stages I-IV (HR = 1.74, 95% CI: 1.49–2.02, P < .001), others (HR = 1.65, 95% CI: 1.30–2.10, P < .001), and NR (HR = 12.29, 95% CI: 5.12–29.50, P < .001).